Haemonetics Corporation stocks have been trading up by 17.46 percent following upbeat sentiment on its stronger-than-expected earnings performance.
Click Here for a Millionaire's POV on Trading HAE
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Citigroup upgraded Haemonetics (HAE) from Neutral to Buy and raised its price target to $123, above the current analyst mean target near $108.40.
- Citi sees earnings upside for HAE from a new non-exclusive CSL supply deal, estimating each 10% share recapture adds $0.13 to EPS.
- Shares of Haemonetics gained about 2.4% after the upgrade and target hike from $92 to $123, though trading volume stayed below average.
- The Vivasure acquisition for HAE triggered a $6.1M milestone payment and set up as much as $10M in future earnouts tied to Vivasure revenues.
- Haemonetics scheduled its Q2 FY2027 results and conference call for 2026/11/05, a key catalyst for traders tracking the CSL and Vivasure stories.
Live Update At 16:46:49 EDT: On Thursday, October 08, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 17.46%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Haemonetics (HAE) has been grinding higher, then exploded on the Citi upgrade. On the daily chart, HAE spent weeks stuck around $104–$109. Then it ripped from a prior close near $101.71 to finish the latest session at $119.47, after hitting $121 intraday. That’s a textbook breakout above a tight range.
Intraday, HAE’s 5‑minute chart shows a big gap from premarket trading in the low $120s, early volatility down to $111.66 at the open, and then a steady reclaim back to the high $110s and low $120s. This is classic “news gap, shakeout, then grind higher” action that momentum traders study every day.
Fundamentally, Haemonetics prints strong gross margins around 59%, but runs leaner at the bottom line with roughly 7% net margin. The P/E near 50.0 and price-to-sales around 3.5 tell traders the market already prices in growth. Debt is meaningful, with total debt-to-equity at 1.4, but the current ratio at 3.1 and interest coverage near 21.8 show HAE handling its obligations.
More Breaking News
- HUM Stock Jumps As Wall Street Bets On Medicare Advantage Rebound
- SPOT Stock Climbs As Wall Street Hikes Bullish Targets
- Spotify Stock Draws Bullish Targets As AI, Content Bets Build
- NOK Stock Slides As European ADR Weakness Deepens
Cash flow backs that up: recent quarterly operating cash flow of about $52.3M and free cash flow around $44.4M give Haemonetics room to fund deals like Vivasure while still paying down debt. For traders, HAE looks like a growth‑priced medtech name that now has fresh catalyst juice.
Why Traders Are Watching HAE Right Now
Haemonetics is suddenly front and center on momentum screens because a major bank just shifted its stance. Citigroup upgraded HAE from Neutral to Buy and took its price target all the way up to $123 from $92. That new target also sits above the current analyst mean near $108.40, which effectively plants a new flag higher on the chart for traders to key off.
The heart of Citi’s argument is earnings leverage. Haemonetics signed a new non-exclusive supply agreement with CSL, and Citi expects real upside from that deal. Their math is simple and powerful: for every 10% share HAE recaptures in that CSL-related business, they estimate EPS increases by $0.13. For a company already posting quarterly diluted EPS around $0.72, that kind of incremental boost gets noticed.
The market reaction backed it up. Haemonetics shares popped roughly 2.4% after the upgrade and target hike, with the stock trading around $108 before pushing higher toward the $120 area. Volume stayed below average, which is important. It tells traders that the move was driven more by price re-rating than a full-on crowd rush. If bigger funds pile in later, HAE could see a second leg.
At the same time, Haemonetics is working the longer game with its Vivasure acquisition. The company triggered a $6.1M milestone payment to Orchestra BioMed, completing $11M of total consideration so far and leaving up to $10M in earnouts tied to future Vivasure revenues. The PerQseal Elite bioabsorbable vessel closure system is at the core of that deal. HAE is clearly willing to spend now in exchange for a future revenue stream.
The milestone shows Vivasure integration is tracking to plan, not stalling. That combination — CSL-driven near-term earnings upside and Vivasure as a pipeline growth driver — is exactly the kind of layered story active traders like to track.
Conclusion
For active traders, Haemonetics (HAE) is shifting from sleepy medtech to a live catalyst name. The Citi upgrade to Buy with a $123 target gives HAE a clear narrative: a high‑margin business with room to expand earnings through its CSL supply agreement. When a bank spells out that every 10% share recapture may add $0.13 to EPS, momentum traders listen. The recent breakout above the $110 zone confirms the market is starting to price that in.
On the strategic side, HAE’s Vivasure acquisition is quietly building another leg of the story. The $6.1M milestone payment and up to $10M in future earnouts are not pocket change, but they’re manageable against Haemonetics’ free cash flow and balance sheet. If PerQseal Elite ramps, traders will eventually see it in revenue growth and margin trends.
All eyes now turn to 2026/11/05, when Haemonetics reports Q2 FY2027 results and hosts its conference call. That’s where the CSL thesis and Vivasure progress will get tested in real numbers and guidance. Between now and then, HAE’s chart is the scoreboard.
As Tim Sykes always says, “Trading success isn’t about predicting the future, it’s about reacting to patterns and catalysts in real time.” That mindset lines up closely with another core trading principle: As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. For HAE, the catalysts are here — the job now is to study the price action, manage risk, and treat every trade as an educational opportunity, not a guarantee. This coverage is for educational and research purposes only, not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.